Alpine Immune falls after stopping enrollment in cancer drug studies

Hanall Biopharma

24/10/2022 13:08

** Shares of biopharma co Alpine Immune Sciences  ALPN.O 
down ~8% at $5.30 before the bell 
    ** Co says it is voluntarily terminating enrollment in
studies, NEON-1 and NEON-2 involving davoceticept, its drug
intended for cancer treatment  urn:newsml:reuters.com:*:nBw86PG3Ra
    ** Decided to stop enrollment in davoceticept studies after
co was notified of a second death in the NEON-2 study - ALPN
    ** Co says second death in study also attributed to
cardiogenic shock, a condition in which the heart is unable to
pump enough oxygen-rich blood to the body's organs
    ** NEON-2 study had previously been put on partial clinical
hold by the U.S. health regulator after report of first adverse
event  urn:newsml:reuters.com:*:nL3N2VA3KT
    ** ALPN adds it now plans to focus and expedite development
of its drug candidate, ALPN-303, aimed at treatment of multiple
autoimmune and inflammatory conditions 
    ** As of last close, ALPN down ~59% YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))